| U.S. Brand Names |
| Trobicin® |
 |
| Generic Available |
|
No |
|
| Synonyms |
| Spectinomycin Hydrochloride |
|
| Pharmacological Index |
|
Antibiotic, Miscellaneous |
|
| Use |
|
Treatment of uncomplicated gonorrhea |
|
| Pregnancy Risk Factor |
|
B |
|
| Contraindications |
|
Hypersensitivity to spectinomycin or any component |
|
| Warnings/Precautions |
|
Since spectinomycin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of diagnosis and 3 months later. |
|
| Adverse Reactions |
|
<1%: Dizziness, headache, chills, urticaria, rash, pruritus, nausea, vomiting, pain at injection site |
|
| Overdosage/Toxicology |
|
Symptoms of overdose include paresthesia, dizziness, blurring of vision, ototoxicity, renal damage, nausea, sleeplessness, decrease in hemoglobin |
|
| Drug Interactions |
|
No data reported |
|
| Stability |
|
Use reconstituted solutions within 24 hours; reconstitute with supplied diluent only |
|
| Mechanism of Action |
|
A bacteriostatic antibiotic that selectively binds to the 30s subunits of ribosomes, and thereby inhibiting bacterial protein synthesis |
|
| Pharmacodynamics/Kinetics |
|
Duration: Up to 8 hours Absorption: I.M.: Rapid and almost completely Distribution: Concentrates in urine; does not distribute well into the saliva Half-life: 1.7 hours Elimination: Excreted almost entirely as unchanged drug in urine (70% to 100%) |
|
| Usual Dosage |
|
I.M.: <45 kg: 40 mg/kg/dose 1 time (ceftriaxone preferred) greater than or equal to 45 kg: See adult dose Children >8 years who are allergic to PCNS/cephalosporins may be treated with oral tetracycline Adults: Uncomplicated urethral endocervical or rectal gonorrhea: 2 g deep I.M. or 4 g where antibiotic resistance is prevalent 1 time; 4 g (10 mL) dose should be given as two 5 mL injections, followed by doxycycline 100 mg twice daily for 7 days Disseminated gonococcal infection: 2 g every 12 hours Dosing adjustment in renal impairment: None necessary Hemodialysis: 50% removed by hemodialysis |
|
| Administration |
|
For I.M. use only |
|
| Mental Health: Effects on Mental Status |
|
May cause dizziness |
|
| Mental Health: Effects on Psychiatric Treatment |
|
None reported |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
This medication can only be administered I.M. You will need to return for follow-up blood tests. Breast-feeding precautions: Consult prescriber if breast-feeding. |
|
| Dosage Forms |
|
Powder for injection: 2 g, 4 g |
|
| References |
|
U.S. Department of Health and Human Services, "1993 Sexually Transmitted Diseases Treatment Guidelines," MMWR Morb Mortal Wkly Rep, 1993, 42(RR-14). |
|
|
Copyright © 2007 Drugs Area |
